QNTA

Quanta, Inc. [QNTA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

QNTA Stock Summary

Top 10 Correlated Stocks

QNTA


In the News

08:00 22 Mar 2023 QNTA

Medolife Rx Schedules Conference Call with Investment Community To Discuss Third Quarter 2021 Financial and Operational Results and New Updates

BURBANK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that it has scheduled a conference call with investors for Tuesday, November 23rd.

08:30 22 Mar 2023 QNTA

Medolife Rx Announces that the Government of the Dominican Republic is Willing to Include Escozine into its COVID-19 Treatment Regimen

BURBANK, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that its CEO, Dr Arthur Mikaelian, had a successful meeting with the Vice President of the Dominican Republic (DR), Raquel Peña de Antuña, where the official expressed interest in introducing Escozine® into the government's COVID-19 program after reviewing results from the Company's study.

08:30 22 Mar 2023 QNTA

Medolife Rx Reports 257% Increase in Efficacy of Ibuprofen Through Proprietary Polarization Method, Looks to Expand Into Other APIs

BURBANK, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today results from a study on its patented polarization methodology that compared the effectiveness of generic ibuprofen, a well-known pain relief drug that works by lowering inflammation by inhibiting the cyclooxygenase-2 (COX-2) enzyme's activity in the body, versus polarized ibuprofen in inhibition of COX-2 activity in humans. The results showed that polarized ibuprofen was 257% more effective in inhibiting COX-2, which is expressed in inflammation and pain in humans. The result further solidifies the potential applications of polarization on the healthcare industry as a whole, whereas the therapeutic efficacy of active pharmaceutical ingredients (APIs) can be increased through the process, and dosage can be decreased, resulting in fewer side effects and potential damage to the liver.

08:30 22 Mar 2023 QNTA

Medolife Rx Initiates Comparative Study of Its Flagship CBD-based Muscle Rub and Competitor

BURBANK, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that it has initiated a study on its polarized cannabidiol (CBD) muscle rub product, sold under the brand Aelia. The study will analyze the effectiveness of the product in reducing inflammation through the inhibition of cyclooxygenase-2 (COX-2) enzyme activity in the human body and compare the findings with other non-polarized CBD products currently available on the market.

08:30 22 Mar 2023 QNTA

Medolife Rx Files Bi-Annual Report With Ministry of Environment in the Dominican Republic, Details Reservation Expansion and Exceeds Regulatory Expectations

BURBANK, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that it has completed a bi-annual filing with the Ministry of Environment (MOE) of the Dominican Republic (DR), which detailed the expansion of its scorpion reservation and exceeded the expectations of the regulatory body. The MOE expressed further interest in the Company's flagship product, Escozine®, which has recently renewed its registration in the DR as a natural alternative medicine for oncological treatments.

10:47 22 Mar 2023 QNTA

Medolife Rx Launches Ad Campaign With Tony Hawk, Sees Immediate Positive Results

BURBANK, CA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today the successful launch of a digital advertising campaign for its Aelia line of products featuring product spokesperson Tony Hawk. The campaign launched nationwide on September 16, 2021, and has already garnered hundreds of thousands of impressions and resulted in a traffic spike to the Company's website when compared to the previous 20 days.

06:09 22 Mar 2023 QNTA

Medolife Rx Clarifies April 13, 2021 Press Release

BURBANK, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife" or the “Company”), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today two clarifications to its press release, dated April 13, 2021:

10:40 22 Mar 2023 QNTA

Medolife Rx Recaps Successful Attendance at Tony Hawk Event; Saw Significant Product Exposure

BURBANK, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), today recapped their attendance at the Inaugural Tony Hawk's Vert Alert event in Salt Lake City the weekend of August 27 and 28. The Company showcased its rebranded line of consumer wellness products, participated in skateboarding community discussions and events, and met with Hawk himself as well as his management team, where the parties discussed meeting soon to increase their joint initiatives aimed at further reaching the skateboarding community worldwide with Aelia products.

05:15 22 Mar 2023 QNTA

Medolife Rx Reports Second Quarter 2021 Financial and Operational Results, Schedules Conference Call With Investment Community

BURBANK, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today financial results for the second quarter of 2021, and provided an operational update.

11:04 22 Mar 2023 QNTA

Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021

BURBANK, CA, July 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it will hold a webcast and Q&A with the investment community on Tuesday, July 27, at 5 p.m. Eastern Daylight Time.  The purpose of this is to answer questions received from the investment community all at one time in an open forum.

QNTA Financial details

Company Rating
Neutral
Market Cap
81.32K
Income
-6.18M
Revenue
413.57K
Book val./share
-0.01
Cash/share
0
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
23 May 2022
P/E
-0.02
Forward P/E
-
PEG
0
P/S
0.34
P/B
-0.02
P/C
-
P/FCF
-0.18
Quick Ratio
-
Current Ratio
0.11
Debt / Equity
-1.45
LT Debt / Equity
-0.09
-
-
EPS (TTM)
0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-71.43%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-46.53%
EPS Q/Q
-109.68%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-364%
ROE
77%
ROC
0.79%
Gross Margin
97%
Oper. Margin
-1074%
Profit Margin
-1518%
Payout
-
Shs Outstand
406.59M
Shs Float
372.84M
-
-
-
-
Target Price
-
52W Range
1.0E-4-0.0075
52W High
-
52W Low
-
RSI
54.64
Rel Volume
-
Avg Volume
214.17K
Volume
1000
Perf Week
0%
Perf Month
0%
Perf Quarter
100%
Perf Half Y
100%
-
-
-
-
Beta
1.69
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0002
Change
0%

QNTA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-04-302018-04-302018-12-312020-12-31 2021-12-31
Revenue per share
000.030.020
Net income per share
-0.01-0.01-0.14-0.14-0.04
Operating cash flow per share
00-0.05-0.04-0.02
Free cash flow per share
00-0.05-0.04-0.02
Cash per share
00000
Book value per share
-0.01-0.010.01-0.04-0.02
Tangible book value per share
-0.01-0.010.01-0.04-0.02
Share holders equity per share
-0.01-0.010.01-0.04-0.02
Interest debt per share
000.010.070.02
Market cap
44M59.35M85.62M3.89M1.46M
Enterprise value
44.04M59.37M85.76M6.53M4.46M
P/E ratio
-330.84-331.64-14.79-0.48-0.18
Price to sales ratio
0067.473.362.16
POCF ratio
-1.09K-1.26K-38.54-1.84-0.43
PFCF ratio
-1.09K-1.26K-36.65-1.75-0.42
P/B Ratio
-320.57-211.68335.21-1.49-0.38
PTB ratio
-320.57-211.68335.21-1.49-0.38
EV to sales
0067.585.646.62
Enterprise value over EBITDA
-341.42-331.75-16.18-1-0.59
EV to operating cash flow
-1.09K-1.26K-38.61-3.08-1.3
EV to free cash flow
-1.09K-1.26K-36.72-2.94-1.29
Earnings yield
00-0.07-2.1-5.67
Free cash flow yield
00-0.03-0.57-2.37
Debt to equity
-1.23-1.020.74-1.28-1.44
Debt to assets
5.2945.030.434.526.2
Net debt to EBITDA
-0.32-0.1-0.03-0.4-0.4
Current ratio
0.030.020.290.060.12
Interest coverage
00-24.26-4.25-13.34
Income quality
0.30.260.380.260.41
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
004.814.811.7
Research and developement to revenue
000.280.390.67
Intangibles to total assets
00000
Capex to operating cash flow
000.050.050.01
Capex to revenue
00-0.09-0.09-0.06
Capex to depreciation
00-0.44-0.3-0.26
Stock based compensation to revenue
00000
Graham number
0.030.050.130.370.12
ROIC
-4.7528.59-14.7-7.4-9.28
Return on tangible assets
-4.15-28.1-13-11.03-9.3
Graham Net
-0.01-0.010-0.06-0.02
Working capital
-163.43K-280.37K-134.24K-2.44M-3.02M
Tangible asset value
-137.26K-280.37K255.41K-2.61M-4.61M
Net current asset value
-163.43K-280.37K-134.24K-3.19M-5.08M
Invested capital
-0.32-0.090.7-1.01-0.79
Average receivables
009.78K10.12K385
Average payables
00000
Average inventory
0009.61K58.69K
Days sales outstanding
005.630.220.05
Days payables outstanding
00000
Days of inventory on hand
00024.94249.81
Receivables turnover
0064.871.69K7.92K
Payables turnover
00000
Inventory turnover
00014.631.46
ROE
0.970.64-22.663.132.16
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
0.010000
Net income per share
-0.05-0.01-0.01-0.010
Operating cash flow per share
-0.01-0.01000
Free cash flow per share
-0.01-0.01000
Cash per share
00000
Book value per share
-0.06-0.02-0.02-0.02-0.01
Tangible book value per share
-0.06-0.03-0.02-0.02-0.01
Share holders equity per share
-0.06-0.02-0.02-0.02-0.01
Interest debt per share
0.040.020.020.020.01
Market cap
2.66M7.07M6.6M1.31M1.43M
Enterprise value
4.97M9.49M9.87M4.31M4.34M
P/E ratio
-0.23-0.79-1.58-0.16-0.41
Price to sales ratio
8.1460.562.8110.4621.45
POCF ratio
-3.4-4.21-8.72-6.48-5.74
PFCF ratio
-3.34-4.18-8.57-6.48-5.74
P/B Ratio
-0.68-2.17-1.62-0.34-0.39
PTB ratio
-0.68-2.17-1.62-0.34-0.39
EV to sales
15.2181.1794.0234.564.93
Enterprise value over EBITDA
-1.77-4.45-12.76-2.39-6.22
EV to operating cash flow
-6.35-5.65-13.05-21.37-17.38
EV to free cash flow
-6.25-5.61-12.84-21.37-17.38
Earnings yield
-1.11-0.32-0.16-1.56-0.61
Free cash flow yield
-0.3-0.24-0.12-0.15-0.17
Debt to equity
-1.33-1.58-1.4-1.44-1.45
Debt to assets
4.473.856.336.26.7
Net debt to EBITDA
-0.82-1.13-4.24-1.67-4.17
Current ratio
0.220.290.110.120.11
Interest coverage
-29.92-42.68-4.33-6.38-6.2
Income quality
0.250.640.620.150.28
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
9.6300011.29
Research and developement to revenue
0.40.9610.841.57
Intangibles to total assets
00000
Capex to operating cash flow
0.020.010.0200
Capex to revenue
-0.04-0.12-0.1200
Capex to depreciation
-0.34-0.36-0.3300
Stock based compensation to revenue
00000
Graham number
0.250.090.050.070.03
ROIC
-5.59-3.31-1.16-1.48-1.04
Return on tangible assets
-2.54-1.67-1.16-2.29-1.1
Graham Net
-0.08-0.03-0.03-0.03-0.02
Working capital
-2.17M-1.93M-3.09M-3.02M-3.01M
Tangible asset value
-4.04M-3.81M-4.8M-4.61M-4.56M
Net current asset value
-4.59M-4.34M-5.3M-5.08M-4.98M
Invested capital
-0.67-0.83-0.81-0.79-0.79
Average receivables
74.89K149.1K74.55K42.5148
Average payables
00000
Average inventory
31.61K61.05K75.91K85.95K85.72K
Days sales outstanding
41.08114.8200.060.28
Days payables outstanding
00000
Days of inventory on hand
113.22157.480.96-485.62265.21
Receivables turnover
2.190.7801.47K316.53
Payables turnover
00000
Inventory turnover
0.790.571.11-0.190.34
ROE
0.760.680.260.530.24
Capex per share
00000

QNTA Frequently Asked Questions

What is Quanta, Inc. stock symbol ?

Quanta, Inc. is a US stock , located in Burbank of Ca and trading under the symbol QNTA

What is Quanta, Inc. stock quote today ?

Quanta, Inc. stock price is $0.0002 today.

Is Quanta, Inc. stock public?

Yes, Quanta, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap